SUBCUTANEOUS IMMUNOGLOBULIN 16.5% (CUTAQUIG©) IN PRIMARY IMMUNODEFICIENCY DISEASE: SAFETY, EFFICACY, AND PATIENT EXPERIENCE WITH ENHANCED INFUSION REGIMENS (IMAGE)

Yankee Public Relations

SUBCUTANEOUS IMMUNOGLOBULIN 16.5% (CUTAQUIG©) IN PRIMARY IMMUNODEFICIENCY DISEASE: SAFETY, EFFICACY, AND PATIENT EXPERIENCE WITH ENHANCED INFUSION REGIMENS

Caption

Octapharma USA poster presented at the Clinical Immunology Society 2023 Annual Meeting. The poster reports the findings of the Phase 3 clinical trial: Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases.

Credit

Octapharma USA

Usage Restrictions

N/A

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.